Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
Conditions
Interventions
CMG190303(Dapagliflozin/Rosuvastatin)
Comparator 1: Dapagliflozin/Rosuvastatin placebo
+1 more
Locations
24
South Korea
Hallym university sungsim medical center
Anyang, South Korea
Buchon sejong hospital
Buchon, South Korea
Inje university heaundea paik hospital
Busan, South Korea
Soonchunhyang cheonan university hospital
Cheonan, South Korea
Keimyung University Dongsan Medical Center
Daegu, South Korea
Daejeon eulji medical center, eulji university
Daejeon, South Korea
Start Date
April 19, 2024
Primary Completion Date
November 4, 2026
Completion Date
February 1, 2027
Last Updated
January 15, 2026
NCT07232537
NCT06815081
NCT06003153
NCT06278207
NCT07051005
NCT07296484
Lead Sponsor
CMG Pharmaceutical Co. Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions